Loading...
•
Jun 30, 2021
Lineage Q2 2021 Earnings Report
Reported second quarter 2021 financial results and highlighted additional progress from clinical cell therapy programs.
Key Takeaways
Lineage Cell Therapeutics reported financial and operating results for the second quarter 2021, with revenue of $0.5 million and a net loss attributable to Lineage of $4.8 million, or $0.03 per share.
Lineage continued to make significant operational and developmental progress during the second quarter.
OpRegen has generated the only known cases of retinal tissue restoration in previously confirmed atrophic areas in humans.
Lineage will soon be returning OPC1 to clinical testing in a device safety study, which will include chronic spinal cord injury patients.
Lineage was added to the Russell 3000® Index, which will improve awareness of the continued success of the company's cell transplant approach.
Forward Guidance
Lineage cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements and are subject to risks and uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...